GamaMabs Pharma to present new data on GM102 at two upcoming scientific conferences in November

New clinical data in Granulosa Cell Tumor (GCT) patients will be presented at the EORTC–NCI–AACR 2018 Symposium and GM102 unique T-cell activation mechanism at the AACR 2018 Conference on Tumor Immunology and Immunotherapy

Paris and Toulouse, France, November 12, 2018 – GamaMabs Pharma, a biotechnology company developing optimized therapeutic antibodies targeting the Anti-Müllerian Hormone Receptor II (AMHRII) for the treatment of cancer, today announces its presentation of new data regarding its First-In-Class GM102 antibody at two upcoming conferences.

Clinical data for 20 Granulosa Cell Tumor patients treated with GM102 in the C101 clinical study, will be presented at the EORTC–NCI–AACR 2018 Symposium, Dublin (Ireland), on November 13-16, 2018. The poster describes safety and hints of activity of GM102 in this orphan disease with high unmet need and no approved therapy.

“Following the first results of the C101 study in gynecological cancers published at ASCO this year, we will present additional clinical data for the subset of granulosa ovarian cancer patients who do not have therapeutic alternatives at this stage in their disease,” said Dr. Isabelle Tabah-Fisch, Chief Medical Officer at GamaMabs Pharma

Unveiled activation of T-cells by GM102 following macrophage activation and synergy with immune-checkpoint inhibitors targeting T-cells, will be presented at the AACR 2018 Conference on Tumor Immunology and Immunotherapy, Miami (Florida) on November 27-30.

“We are looking forward to presenting new data on T-cell activation induced by GM102, confirming the potential of our mAb as a single agent and in combination with immune-checkpoint inhibitors,” said Jean-François Prost, Chief R&D Officer at GamaMabs.

The presentation details are:

  • EORTC–NCI–AACR Symposium 2018
    • Title: ‘GM102, a first-in-class monoclonal glyco-engineered antibody (Ab) targeting Anti-Mullerian-Hormone-Receptor II (AMHRII): safety and hints of activity in Granulosa Cell Tumors (GCT)’, Leary A.
    • Session: Late Breaking Poster Presentation
    • Abstract number: 15LBA
    • Date and time: November 16, 2018, 10am ­– 2pm
    • Location: Exhibition Hall, The Convention Centre, Dublin (CCD)
  • AACR Conference on Tumor Immunology and Immunotherapy
    • Title: ‘GM102, a low fucosylated anti-Müllerian Hormone type II Receptor (AMHRII) antibody, promotes in vitro antitumoral activities of innate (macrophages) and adaptative (CD4+ and CD8+ T cells) immune cells’
    • Poster number: B77
    • Date and time: Thursday, November 29, 5pm – 7pm (EST)
    • Session category/title: Poster Session B
    • Location: Loews, Miami Beach, rooms Americana 3 and 4

GM102 is a first-in-class glyco-engineered (low-fucose) monoclonal antibody selectively targeting AMHRII-expressing tumors. AMHRII, an embryonic receptor involved in the regression of the Müllerian ducts in the male embryo, is constitutively expressed in ovarian granulosa tumors (GCT) and is re-expressed in a majority of tumor samples in a wide range of gynecological and non-gynecological tumors such as colorectal and lung cancers, hepatocarcinoma or renal cell carcinoma. GM102 is currently being studied in two clinical trials, a phase 1b in recurrent gynecological cancers and a phase 2 in advanced or metastatic colorectal cancers.

GM102 exerts its anti-tumor activity through NK cell and macrophage engagement in the tumor microenvironment, resulting in enhanced tumor phagocytosis and subsequent T cell activation.

Following presentation, the two posters will be available on the publication page of GamaMabs’ website.

About GamaMabs Pharma

GamaMabs Pharma, a French immuno-oncology biotechnology company, is a leader in the development of optimized antibodies targeting AMHRII for the treatment of cancer. GamaMabs’ first-in-class proprietary therapeutic monoclonal antibodies have the potential for broad applications in cancer. GM102 antibody, which targets the Anti-Müllerian Hormone Receptor II (AMHRII/MISR2), is in phase 1b and phase 2 studies in various solid tumors. The company develops low-fucose EMABling® antibodies (license granted by LFB) with increased tumor cell killing properties through a breakthrough activation of immune cells. GamaMabs also has a licensing agreement with MedImmune (USA) to develop an Antibody Drug Conjugate targeting cancer.

Version française